Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CME GROUP INC.CME · Entity 2909 | Sr MD, General Counsel | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CME GROUP INC.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Class ASEC Table I · non-derivative | Direct | 3,598 |
Ending reported balance
After 2026-09-16 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-15 · Grant · Acquired 784 · Balance 3,839 F1: Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4. Row 2 · 2026-09-15 · Tax withholding · Disposed 43 · Balance 3,796 F2: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. Row 3 · 2026-09-15 · Tax withholding · Disposed 47 · Balance 3,749 F2: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. Row 4 · 2026-09-15 · Tax withholding · Disposed 57 · Balance 3,692 F2: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. Row 5 · 2026-09-15 · Tax withholding · Disposed 50 · Balance 3,642 F2: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. Row 6 · 2026-09-16 · Tax withholding · Disposed 44 · Balance 3,598 F2: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4.
F2: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 17, 2026 20:23 UTC | CME GROUP INC. CME · Entity 2909 | Tax withholdingCommon Stock Class A | 44 | $272.46 | $11,988.24 |
DisclosureSEC source: 0002153052-26-000002 · wk-form4_1789676628.xml · nonDerivative · entry 6 Marchese John Clifford · CIK 0002153052 · Sr MD, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,598 F2 · kind: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:23 UTC | CME GROUP INC. CME · Entity 2909 | Tax withholdingCommon Stock Class A | 50 | $275.09 | $13,754.50 |
DisclosureSEC source: 0002153052-26-000002 · wk-form4_1789676628.xml · nonDerivative · entry 5 Marchese John Clifford · CIK 0002153052 · Sr MD, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,642 F2 · kind: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:23 UTC | CME GROUP INC. CME · Entity 2909 | Tax withholdingCommon Stock Class A | 57 | $275.09 | $15,680.13 |
DisclosureSEC source: 0002153052-26-000002 · wk-form4_1789676628.xml · nonDerivative · entry 4 Marchese John Clifford · CIK 0002153052 · Sr MD, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,692 F2 · kind: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:23 UTC | CME GROUP INC. CME · Entity 2909 | Tax withholdingCommon Stock Class A | 47 | $275.09 | $12,929.23 |
DisclosureSEC source: 0002153052-26-000002 · wk-form4_1789676628.xml · nonDerivative · entry 3 Marchese John Clifford · CIK 0002153052 · Sr MD, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,749 F2 · kind: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:23 UTC | CME GROUP INC. CME · Entity 2909 | Tax withholdingCommon Stock Class A | 43 | $275.09 | $11,828.87 |
DisclosureSEC source: 0002153052-26-000002 · wk-form4_1789676628.xml · nonDerivative · entry 2 Marchese John Clifford · CIK 0002153052 · Sr MD, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,796 F2 · kind: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:23 UTC | CME GROUP INC. CME · Entity 2909 | GrantCommon Stock Class A | 784 | $275.09 | $215,670.56 |
DisclosureSEC source: 0002153052-26-000002 · wk-form4_1789676628.xml · nonDerivative · entry 1 Marchese John Clifford · CIK 0002153052 · Sr MD, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,839 F1 · kind: Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.